Clinical trials: Diabetes, Type II
Diabetes, Diabetes Mellitus, Type 2
A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs
This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide and insulin degludec both in combination with metformin in Japanese subjects with type 2 diabetes…
- Trial name
- DUAL™ II Japan (NCT02911948)
- Testing
- Insulin degludec/liraglutide, Insulin degludec
- Where
- 38 sites in Japan
- Volunteers
- 210 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients
This trial is conducted globally. The aim of this trial is to compare stepwise insulin intensification of biphasic insulin aspart (BIAsp) 30 and basal-bolus therapy with insulin glargine and insulin aspart in insulin naïve type 2…
- Trial name
- NCT02453685
- Testing
- biphasic insulin aspart 30, insulin glargine, insulin aspart
- Where
- 41 sites in Australia, Bulgaria and 7 more
- Volunteers
- 335 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Coronary Artery Disease
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
The purpose of this study is to determine whether bromodomain extraterminal domain (BET) inhibition treatment with RVX000222 in high-risk type 2 diabetes mellitus patients with coronary artery disease increases the time to major…
- Trial name
- BETonMACE (NCT02586155)
- Testing
- Apabetalone, Atorvastatin, Rosuvastatin
- Where
- 214 sites in Argentina, Australia and 13 more
- Volunteers
- 2,425 people
- Sponsor
- Resverlogix Corp
Type 2 Diabetes Mellitus
A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)
The purpose of this study is to assess the safety and efficacy of omarigliptin (MK-3102), dosed once-weekly in participants with T2DM who have inadequate glycemic control on diet and exercise.
- Trial name
- NCT01717313
- Testing
- Omarigliptin, Metformin, Glimepiride
- Volunteers
- 329 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes
The main purpose of this study is to compare the effectiveness of Human Regular U-500 Insulin three times a day versus twice a day.
- Trial name
- NCT01774968
- Testing
- Human Regular U-500 Insulin
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 325 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MK-8521. Part 1 primary hypothesis: Administration of single subcutaneous (SC) doses of MK-8521 is sufficiently safe and well- tolerated…
- Trial name
- NCT02055547
- Testing
- MK-8521 35μg, MK-8521 100μg, MK-8521 125μg
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
The purpose of this research study is to evaluate the efficacy and safety of an empagliflozin dosing regimen and one dose of linagliptin in patients with type 2 diabetes who are aged 10 to below 18 years and are currently taking…
- Trial name
- NCT03429543
- Testing
- Metformin, Insulin, Linagliptin
- Where
- 83 sites in United States, Argentina and 12 more
- Volunteers
- 175 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 2
Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes
This trial was conducted in Asia, Europe and South America. The aim of this trial was to confirm efficacy of subject driven titration (individually adjusted) of biphasic insulin aspart 30 (BIAsp 30) twice daily in terms of…
- Trial name
- SimpleMix™ (NCT01427920)
- Testing
- biphasic insulin aspart 30
- Where
- 41 sites in Argentina, China and 4 more
- Volunteers
- 348 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, High Blood Sugar
Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus
This is a 24-week randomised, multi-centre phase III study to evaluate the efficacy and safety of dapagliflozin as monotherapy in Japanese subjects with Type 2 diabetes mellitus who have inadequate glycemic control with diet and…
- Trial name
- NCT01294423
- Testing
- Dapagliflozin
- Where
- 26 sites in Japan
- Volunteers
- 261 people
- Sponsor
- AstraZeneca
Diabetes Mellitus
Evaluation of an Ascensia Blood Glucose Meter and App System
The purpose of this study is to assess the usability of the Onyx system in the hands of subjects with Insulin Dependent Diabetes Mellitus (IDDM) or insulin-using subjects with Non-IDDM.
- Trial name
- NCT02568384
- Testing
- Onyx BG Meter / App System
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Ascensia Diabetes Care
Type 2 Diabetes, Insulin Resistance
PK/PD Study of U-500 Regular Insulin
The purpose of this study is to learn more about how U500 regular insulin can be effectively be used to treat type 2 diabetes. Most insulin treated patients with type 2 diabetes take U100 insulin, but if they require large doses…
- Conditions
- Type 2 Diabetes, Insulin Resistance, High Insulin Requirements
- Trial name
- NCT02148250
- Testing
- U-500 insulin, 100 syringe units, U-500 insulin, 200 syringe units
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Minnesota
Type 2 Diabetes Mellitus
30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
A 30-week extension to a 24-week study assessing the hemoglobin A1c (HbA1c)- and fasting plasma glucose (FPG)-lowering efficacy of the combination of sitagliptin and pioglitazone in patients with type 2 diabetes mellitus (T2DM)…
- Trial name
- NCT01028391
- Testing
- Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d., Metformin
- Volunteers
- 317 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe, and North America. The aim of this clinical trial is to compare the efficacy and safety of NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) in subjects with type 2…
- Trial name
- BEGIN™ (NCT01068678)
- Testing
- insulin degludec, insulin glargine
- Where
- 99 sites in United States, Canada and 6 more
- Volunteers
- 460 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Safety and Feasibility of a Novel Endoscopic Intervention for the Treatment of Type II Diabetes
This is an open-label study to assess the safety and feasibility of the DyaMX device for endoscopic duodenal mucosal regeneration in individuals with type 2 diabetes inadequately controlled on glucose-lowering medications.
- Trial name
- REGENT-1 (NCT04725890)
- Testing
- The DyaMX Device
- Where
- 2 sites in Australia
- Volunteers
- 65 people
- Sponsor
- Endogenex, Inc.
Type 2 Diabetes Mellitus, Secondary Hypogonadism
Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus
The purpose of this study is to determine the effect the investigative drug has on glycemic control in men with type 2 diabetes mellitus (T2DM) and secondary hypogonadism
- Trial name
- NCT01191320
- Testing
- Androxal
- Where
- 18 sites in United States
- Volunteers
- 102 people
- Sponsor
- Repros Therapeutics Inc.
Type 2 Diabetes Mellitus
Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes
Although the efficacy and safety profile of exenatide has been well established, few data exist on the real world results of exenatide treatment in specific populations and clinical settings.
- Trial name
- NCT01060059
- Testing
- exenatide, basal insulin
- Where
- 50 sites in Italy
- Volunteers
- 888 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
Primary Objective: To demonstrate the superiority of Sotagliflozin versus placebo on hemoglobin A1c (HbA1c) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic control with metformin.
- Trial name
- NCT02926950
- Testing
- Sotagliflozin (SAR439954), Metformin
- Where
- 93 sites in United States, Canada and 2 more
- Volunteers
- 518 people
- Sponsor
- Lexicon Pharmaceuticals
Diabetes Mellitus, Non-Insulin-Dependent
The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus
The efficacy and safety study of saxagliptin 5mg, once daily for 24 weeks in patients with type 2 diabetes mellitus.
- Trial name
- SUNSHINE (NCT01608724)
- Testing
- Saxagliptin
- Where
- 37 sites in China
- Volunteers
- 2,165 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Comparison Effects Of Different Exercise Approaches On Type 2 DM Women
Type 2 Diabetes Mellitus (T2DM) is one of the most common metabolic diseases with a complex, multifactorial etiology, and is a chronic disease with various clinical and biochemical manifestations.
- Trial name
- NCT05479435
- Testing
- Blue Prescription Exercise Program, Video Based Home Exercise Program, Supervised Group Exercise Program
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Istanbul Medipol University Hospital
Type 2 Diabetes
A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)
This study will assess the pharmacokinetics of two formulations of MK-1006. The primary hypothesis of this study is that the MK-1006 area under the curve (0 to infinity) and maximum concentration after administration of a single…
- Trial name
- NCT00979459
- Testing
- MK-1006 DFC, MK-1006 FCT
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.